Hematology - Apr 30, 2015 Edition

Can't see this email? View it online

	Hematology
	The latest hematology news from News Medical

The next generation Hemo Control – take control of your connectivity

The new Hemo Control from EKF Diagnostics not only provides accurate hemoglobin and hematocrit results in one simple test but now enables full upgrade with Data Management functionality as required, giving complete flexibility over future connectivity options via its bi-directional interface.

As well as giving best-in-class performance, accuracy and reliability in hemoglobin testing, Hemo Control can easily connect to most hospital and laboratory systems.

Visit ekfdiagnostics.com for more information.

	Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.

	EMD Millipore launches Magna ChIRP RNA Interactome Kits for analyzing chromatin-associated RNAs EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced Magna ChIRP™ RNA Interactome Kits, which allow researchers to more easily identify, recover and analyze regions of chromatin that interact with chromatin-associated RNAs such as long non-coding RNA (lncRNA).

			Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

			Lung cancer surgery patients at higher risk of developing venous thromboembolism New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery.

	Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

	MGH researchers find probable mechanism associated with risk of developing serious diseases Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications.

	Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death.

	CML guidelines highlight need for TKI switch timing, choice A review of the European LeukemiaNet guidelines on the care of patients with chronic myeloid leukaemia highlights the need for research into the timing and use of second-line and third-line tyrosine kinase inhibitors.

	Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Pradaxa's maker, Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for its blood thinner to treat DVT and PE.

	Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon Without a doubt, one of the most significant developments in thoracic surgery was the advent of video-assisted thoracoscopic surgery or VATS in the 1990s...

	Novel treatment strategy targets treatment-resistant CML Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors.

	EKF launches next generation Hemo Control POC hemoglobin analyzer Available as a cost effective basic device which stores up to 4000 patient results, the new Hemo Control offers enhanced on-board Data Management (DM) functions following upgrade with the DM ‘add pack’ if required at a later date...

	Purdue University study sheds light on how decitabine drug reverses cell damage A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment.

	Research provides insights into the ability of FL118 to overcome treatment resistance The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance.

Website: www.news-medical.net

Email: [email protected]

Telephone: +44 (0)161 457 7150

AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.

Not interested anymore?
Unsubscribe or
Update Your Newsletter Subscriptions